Gilead CMO Merdad Parsey to depart early 2025; successor search begins

GILEAD SCIENCES, INC.

Chief Medical Officer Merdad Parsey, M.D., Ph.D., will leave Gilead early next year.
Parsey will remain CMO until Q1 2025 to assist with transition while successor is identified.
He joined Gilead in November 2019 and oversaw expansion of pipeline to 54 ongoing clinical trials.
CEO Daniel O'Day praised Parsey's role in doubling the portfolio and advancing virology, oncology, and inflammation.
No formal departure date; transition expected through Q1 2025 or as mutually agreed.

item 5.02 item 9.01

Executive movements

Machine-extracted from this filing. Every card cites the SEC source. See all recent executive movements.

Departed

Merdad V. Parsey

Chief Medical Officer

GILD · GILEAD SCIENCES, INC.

Filed: July 17, 2024, 7:59 PM ET

announced that its Chief Medical Officer, Merdad V. Parsey, M.D., Ph.D., will leave the Company.

Key facts

Extracted from this filing and checked against the source text.

Executive change SEC 8-K Item 5.02 confidence 0.95

Merdad V. Parsey resigned as Chief Medical Officer at GILEAD SCIENCES, INC..

Action: resigned
Role: Chief Medical Officer

Exact text from the filing

announced that its Chief Medical Officer, Merdad V. Parsey, M.D., Ph.D., will leave the Company.

View on SEC.gov

GILEAD SCIENCES, INC. filing history →

Source: SEC EDGAR

accession 0001104659-24-080355

view filing index on sec.gov

view primary document

Machine-readable: JSON · Markdown · Plain text

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.